Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Ipsogen enters breast cancer diagnostic market in Europe

Ipsogen : 02 June, 2008  (New Product)
Ipsogen, a cancer profiler that markets molecular diagnostic assays for leukaemia is to enter the breast cancer diagnostic market with the European launch of MapQuant Dx Genomic Grade.
MapQuant Dx Genomic Grade is the first molecular diagnostic test to accurately measure tumour grade, a consensus indicator of tumour proliferation, risk of metastasis and response to chemotherapy.

Histological tumour grading is considered a decision factor in most national and international guidelines to breast cancer treatment. While it is generally recommended to treat high-grade 組rade 3’ breast carcinoma with chemotherapy because they are chemosensitive and will often recur otherwise. By contrast, most low-grade 'grade 1' tumours should not be treated with chemotherapy because they have a good prognosis and are often chemo-insensitive.

A key clinical issue is how to treat the 50 percent of breast cancers tested today as uncertain/intermediate 組rade 2’ by current methods - based on the visual examination of tumour sections under the microscope.

MapQuant Dx Genomic Grade test directly measures the expression of the 97 genes that best characterise high-grade vs low-grade tumours. It can resolve these 組rade 2’ tumours into either 組rade 1’ or 組rade 3’ tumours in 80 percent of cases.

MapQuant Dx Genomic Grade test is useful when tumour grade information can be decisive for prescribing a chemotherapy. According to most guidelines, this is the case for hormone-sensitive (ER+) node-negative (N-) invasive breast carcinoma.

'In these patients, most grade 2 tumours are treated by chemotherapy and hormonotherapy. It is expected that MapQuant Dx Genomic Grade test downgrades 70 percent of grade 2 tumours to grade 1. This would represent about 50,000 spared chemotherapies in Europe and USA annually,' said Dr Jean-Marc Le Doussal, director of the Breast Cancer Program at Ipsogen.

'MapQuant Dx Genomic Grade demonstrates our commitment to address clinicians' needs by translating the genomic profile of each tumour into reliable, intelligible and decisive information for pathologists, oncologists and patients,' said Vincent Fert, president and chief executive officer of Ipsogen.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   ツゥ 2012 ProHealthServiceZone.com
Netgains Logo